By Ian Walker

GlaxoSmithKline PLC said Tuesday that it has formed a collaboration with Canadian biopharmaceutical company Medicago to develop a novel adjuvanted Covid-19 candidate vaccine.

The pharmaceutical giant said that phase 1 clinical testing will start in the middle of July and that the companies hope to have the vaccine ready for the first half of 2021. The companies also plan to use their technologies to develop vaccines for other infectious diseases.

The vaccine combines Medicago's recombinant coronavirus virus-like particles with Glaxo's pandemic adjuvant system. Coronavirus virus-like particles mimic the structure of the virus responsible for Covid-19, allowing them to be recognized by the immune system.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

July 07, 2020 08:55 ET (12:55 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Gsk.
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Gsk.